Wearable sensor data combined with machine learning predicts fall risk in Parkinson's patients, enhancing preventive care and ...
Merck MRK announced that its phase III KEYLYNK-001 study, evaluating its blockbuster anti-PD-1 therapy Keytruda regimen in ...
A bispecifics can unseat Keytruda. | BioNTech reported an 18-month overall survival rate of 69.7%, beating the cross-trial ...
Researchers at the Foundation have uncovered new insights into the complex link between dopamine and rest tremor in Parkinson ...
ASH: Sarclisa combinations demonstrated significant benefits in newly diagnosed multiple myeloma patients New analysis from the IMROZ phase 3 study of Sarclisa-VRd demonstrated higher and ...